Valuation: Nykode Therapeutics

Market Cap 1.05B 107M 93.83M 86.45M 80.83M 152M 10.08B 154M 1.04B 402M 4.97B 401M 392M 17.27B P/E 2026 *
-4.98x
P/E 2027 * -34.8x
Enterprise Value 566M 57.54M 50.54M 46.56M 43.54M 81.66M 5.43B 83.16M 559M 216M 2.68B 216M 211M 9.3B EV / Sales 2026 *
-
EV / Sales 2027 * 2.93x
Free-Float
56.4%
Yield 2026 *
-
Yield 2027 * -
1 day-0.16%
1 week+2.22%
Current month+2.71%
1 month-1.83%
3 months+7.69%
6 months+37.61%
Current year+33.50%
1 week 3.15
Extreme 3.15
3.29
1 month 2.97
Extreme 2.97
3.6
Current year 2.21
Extreme 2.21
4.1
1 year 1.44
Extreme 1.44
4.1
3 years 1.44
Extreme 1.44
30.18
5 years 1.44
Extreme 1.44
85.3
10 years 1.44
Extreme 1.44
93
Manager TitleAgeSince
Chief Executive Officer 54 01/01/2019
President 49 01/01/2017
Director of Finance/CFO 51 03/05/2021
Director TitleAgeSince
Director/Board Member 54 -
Director/Board Member 57 -
Chairman 45 23/04/2025
Date Insider Type Main position Quantity % Market Cap.
27/03/25BuyCompany 3,000,000 0.9187%
20/12/24Sell

Director

100,000 0.0306%
20/12/24Buy

Director

100,000 0.0306%
Change 5-day change 1-year change 3-year change Capi.($)
-0.16%+2.22%+71.09%-88.22% 107M
+4.43%+2.49%+61.83%+115.25% 55.35B
+1.58%+14.12%+72.87%+85.18% 51.92B
-0.23%-0.98%-14.12%-16.00% 22.76B
+0.98%+9.05%-0.36%+423.40% 22.64B
-0.54%+7.09%+31.68%-14.38% 17.36B
+0.88%+5.78%+30.82%-34.26% 16.1B
+3.02%+12.74%+143.33%+308.04% 13.96B
+0.68%+2.54%+22.28%+168.03% 13.38B
+0.39%+5.56%+27.45% - 12.27B
Average +1.10%+5.46%+44.69%+105.23% 22.58B
Weighted average by Cap. +1.79%+6.54%+46.78%+120.63%

Financials

2026 *2027 *
Net sales - 162M 16.43M 14.43M 13.29M 12.43M 23.31M 1.55B 23.74M 160M 61.78M 764M 61.69M 60.33M 2.66B
Net income -208M -21.12M -18.55M -17.09M -15.98M -29.97M -1.99B -30.52M -205M -79.43M -982M -79.31M -77.57M -3.41B -41.58M -4.22M -3.71M -3.42M -3.2M -5.99M -399M -6.1M -41.02M -15.89M -196M -15.86M -15.51M -683M
Net Debt -485M -49.28M -43.29M -39.88M -37.29M -69.94M -4.65B -71.22M -479M -185M -2.29B -185M -181M -7.97B -578M -58.67M -51.53M -47.48M -44.39M -83.26M -5.54B -84.79M -570M -221M -2.73B -220M -215M -9.48B
Logo Nykode Therapeutics
Nykode Therapeutics ASA is a Norway-based clinical-stage biopharmaceutical platform company dedicated to the discovery and development of vaccines and immunotherapies for cancer and infectious diseases. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The Company develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The Company also has two universal COVID-19 vaccine candidates in development.
Employees
57
Date Price Change Volume
25/06/26 NOK 3.220 -0.16% 124,490
24/06/26 NOK 3.225 -0.62% 417,905
23/06/26 NOK 3.245 0.00% 472,865
22/06/26 NOK 3.245 +0.78% 345,815
19/06/26 NOK 3.220 +2.22% 245,332
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.220NOK
Average target price
5.000NOK
Spread / Average Target
+55.28%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VACC Stock